Optimising orphan drug development

Press Release – Upcoming Speaker

Download

marcus evans life sciences is delighted to announce that Philippe Bordeau will be speaking at our Optimising Orphan Drug Development conference on the 15^th and 16^th of November 2010 in Brussels, Belgium.

Following the recent market developments, the conference aims to combat the ongoing challenges surrounding how to develop orphan drug products for various rare disease classifications and how to market these drugs to gain access in new geographical markets. Philippe will be covering the key topic of overcoming developmental challenges in developing your Cystic Fibrosis treatment, which as a result of marcus evans’s extensive market research, was identified as paramount importance in the current market. Philippe will be amongst an esteemed speaker panel in what promises to be two days of forward-thinking discussion, whilst supported by insightful and relevant peer led case studies.

For further information please get in touch with Ola Samuelsson, Senior Marketing Manager, marcus evans London Tel +44 (0) 20 3002 3276 olas@marcusevansuk.com or visit www.melifesciences.com/orphandd

About Philippe Bordeau: He trained as an engineer in industrial hygiene and is currently CEO of Alaxia SAS, a company he founded in 2008.

Previously, Philippe founded TMI Europe in 1998, a company involved in food business field, sold in 2006 to Bongrain food group to facilitate and accelerate Catallix technology development.

He was nominated in 2002 a trophy for innovation of the IPA, and in parallel, received the Innovation Award from INPI Rhône-Alpes, a trophy awarded to innovative entrepreneurs who have successfully integrated IP in their policy development and management.

Philippe studied and practiced the EU regulations under regular contacts with AFSSA, AFSSAPS, EMEA and North American US FDA.

Philippe worked for many years with Dr. Perraudin on antimicrobial and antiviral properties of secretion liquids and particularly antimicrobial proteins.

At Alaxia, they develop novel medicinal products for respiratory diseases based on their peroxidase plate form (Cystic Fibrosis, Inflammation, sore throat, sinusitis...). Meveol product is designed to enhance respiratory capacity by reducing inflammation and curing infection, including difficult strains to address.

Meveol is recognised orphan drug for CF by both FDA & EMA agencies.

About marcus evans:

A world leading business information company, presenting over 1,000 strategic conferences and summits worldwide, marcus evans’ products include business and economic summits, high level conferences, market analysis, professional training and B2B Internet solutions. The company employs over 2,000 staff in 31 global offices, generating annual revenues of over US$350 million. Above all, marcus evans provides clients with business information and knowledge which enables them to sustain a valuable competitive advantage and makes a positive contribution to their success. To find out more about how you and your organisation can access the very best in business information, please visit us at: www.marcusevans.com

London * New York * San Francisco * Sydney * Hong Kong * Tokyo * Los Angeles * Chicago * Montreal * Paris * Dublin * Mumbai * Philadelphia * Shanghai * Stockholm * Copenhagen * Toronto * Miami * Berlin * Prague * Auckland * Kuala Lumpur * San Diego * Houston * Atlanta * Monte Carlo * Warsaw * Amsterdam * Johannesburg * Monaco * Melbourne

Download

Tailor a specific approach for orphan drug product development across various rare disease classifications and optimise the commercial aspects